论文部分内容阅读
目的:观察胞必佳治疗恶性胸腔积液的临床疗效。方法:采用开放式,25例恶性胸腔积液病人分为单用胞必佳组(12例)和胞必佳十全身化疗组(13例),通过胸腔内注射胞必佳,观察胸水吸收情况及Karnosky评分和生命质量评分的变化。结果:胞必佳治疗恶性胸腔积液,胸水吸收明显,有效率达80％;且Karnosky和生命质量评分均较治疗前有改善(P<0.01);常见副反应为发热、胸痛。结论:胞必佳治疗恶性胸腔积液疗效明显,副反应少。
Objective: To observe the clinical effect of Cytoplasm necessary to treat malignant pleural effusion. Methods: 25 patients with malignant pleural effusion were divided into two groups: metoprolol alone (12 cases) and metopromycin ten whole body chemotherapy group (thirteen cases). The pleural effusion was observed by intrapleural injection. And Karnosky scores and changes in quality of life scores. Results: The cells should be treated with malignant pleural effusion, pleural effusion was obvious, the effective rate was 80%; and Karnosky and quality of life scores were improved than before treatment (P <0.01); common side effects of fever, chest pain. Conclusion: Cephalosporidium is effective in treating malignant pleural effusion with less side effects.